HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial

Autor: Nienke E van Trommel, Gemma G Kenter, John Haanen, Tanja D de Gruijl, Sanne Samuels, Ekaterina S Jordanova, Ton Schumacher, Joost H van den Berg, Bastiaan Nuijen, Jos Beijnen, Marc van Beurden, Noor Alida Maria Bakker, Jossie Rotman, Henry J MAA Zijlmans, Maartje van Ruiten, Karin De Visser

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)

Background Usual vulvar intraepithelial neoplasia (uVIN) is a premalignancy caused by persistent infection with high-risk types of human papillomavirus (HPV), mainly type 16. Even though different treatment modalities are available (eg, surgical exci

Externí odkaz: https://doaj.org/article/c29336b4129f4a6a8b7b92a61e5b1b59

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Autor: Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen

Publikováno v: New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125

Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edf28a71e5a16116e2b0f59cdac9485a
https://research.rug.nl/en/publications/9033fdbd-9e6f-4cca-a35b-50890da9f292

Supplementary Figures 1 through 5 and supplementary Tables 1 through 3 from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

Autor: Els M.E. Verdegaal, Sjoerd H. van der Burg, Jan Oosting, Vincent T.H.B.M. Smit, John B.A.G. Haanen, Joost H. van den Berg, Ellen H.W. Kapiteijn, Merel van Diepen, Marten Visser, Valeria V. Visconti, Sara M. Melief

Figure S1. Kaplan-meier curves of the ACT-treated patients. Figure S2. Immunofluorescent staining of metastatic melanoma tissue with antibodies against CD3, CD8, FoxP3, CD14, CD163, galectin-1, galectin-3 and galectin-9. Figure S3. Macrophage and Tbe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::155da370153efe93c42bd7acc52f6db6
https://doi.org/10.1158/2326-6066.22538216

Supplementary Figure legends from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

Autor: Els M.E. Verdegaal, Sjoerd H. van der Burg, Jan Oosting, Vincent T.H.B.M. Smit, John B.A.G. Haanen, Joost H. van den Berg, Ellen H.W. Kapiteijn, Merel van Diepen, Marten Visser, Valeria V. Visconti, Sara M. Melief

Legends for supplementary Figure 1 through 5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cd9f7e11b8be4fcb6ef3a29b66d9932
https://doi.org/10.1158/2326-6066.22538225.v1

The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones

Autor: Rienk Offringa, Frank Bergmann, Claudia Lauenstein, Aaron Rodriguez-Ehrenfried, Stina L. Wickström, Michael Flossdorf, Anna-Katharina König, John B. A. G. Haanen, Ignacio Heras-Murillo, Lena M. Appel, Jasmin Roth, Oliver Strobel, Rolf Kiessling, Jessica C. Hassel, Tanja Lövgren, Joost H. van den Berg, Johanna Lehmann, Isabel Poschke, Katharina A.M. Lindner

Publikováno v: Clinical Cancer Research. 26:4289-4301

Purpose: During our efforts to develop tumor-infiltrating lymphocyte (TIL) therapy to counter the devastating recurrence rate in patients with primary resectable pancreatic ductal adenocarcinoma (PDA), we found that PDA TILs can readily be expanded i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::99529323d40e3c9057355affc6a41afe
https://doi.org/10.1158/1078-0432.ccr-19-3845